Advertisement
ARKG vs VHT
Which ETF would AI Choose? ARK Genomic Revolution ETF (ARKG) vs. Vanguard Health Care ETF (VHT)
Key Takeaways
- ARK Genomic Revolution ETF (ARKG) is an actively managed thematic fund targeting the genomics revolution, while Vanguard Health Care ETF (VHT) is a passively managed vehicle providing broad exposure to the entire health care sector.
- ARKG maintains a concentrated portfolio of approximately 35 holdings focused on innovative genomics and biotechnology companies, whereas VHT holds roughly 410 stocks across pharmaceuticals, biotechnology, equipment, and services.
- ARKG carries a higher expense ratio of 0.75% compared to VHT’s 0.09%, reflecting its active management and specialized strategy.
- Top holdings in ARKG emphasize smaller, high-growth genomics firms such as 10x Genomics Inc (TXG), Twist Bioscience Corp (TWST), and CRISPR Therapeutics AG (CRSP), while VHT’s largest positions are dominated by established large-cap names including Eli Lilly and Co (LLY), Johnson & Johnson (JNJ), and AbbVie Inc (ABBV).
- ARKG offers concentrated thematic exposure with higher volatility potential, while VHT delivers diversified sector representation with lower cost and broader market-cap coverage.
- Both ETFs provide health care exposure but serve distinct investor objectives: thematic growth versus comprehensive sector allocation.
Introduction
Investors seeking health care exposure often face a choice between specialized thematic strategies and broad sector funds. ARK Genomic Revolution ETF (ARKG) and Vanguard Health Care ETF (VHT) represent two distinct approaches within the same sector. ARKG pursues active, high-conviction bets on genomics innovation, while VHT delivers low-cost, rules-based access to the full spectrum of health care companies. These ETFs do not compete directly but offer alternative positioning for investors balancing growth potential against diversification and cost efficiency in the evolving health care landscape.
ARK Genomic Revolution ETF (ARKG) Overview
ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund (ETF) launched in 2014 that seeks long-term capital growth by investing primarily in equity securities of companies advancing the genomics revolution. The fund targets firms involved in gene therapy, bioinformatics, molecular medicine, and related technologies across health care, information technology, materials, energy, and consumer discretionary sectors. It typically holds 32 to 40 securities with significant concentration in the top positions. Recent top holdings include 10x Genomics Inc (TXG), Twist Bioscience Corp (TWST), Tempus AI Inc (TEM), CRISPR Therapeutics AG (CRSP), and Absci Corp (ABSI). The portfolio is heavily weighted toward health care, particularly biotechnology and life sciences tools. ARKG carries an expense ratio of 0.75% and employs an active, high-conviction rebalancing approach driven by fundamental research rather than an index.
Vanguard Health Care ETF (VHT) Overview
Vanguard Health Care ETF (VHT) is a passively managed exchange-traded fund (ETF) launched in 2004 that seeks to track the performance of the MSCI US Investable Market Health Care 25/50 Index. The fund provides multicapitalization exposure to U.S. health care companies classified under the Global Industry Classification Standard (GICS). It employs full replication when possible and holds approximately 410 stocks. Top holdings typically include Eli Lilly and Co (LLY), Johnson & Johnson (JNJ), AbbVie Inc (ABBV), Merck & Co Inc (MRK), and UnitedHealth Group Inc (UNH). Sector allocations span pharmaceuticals, biotechnology, health care equipment, life sciences tools, and managed care. VHT maintains a low expense ratio of 0.09% and features quarterly rebalancing aligned with its underlying index methodology.
Industry and Thematic Backdrop
The health care sector continues to benefit from long-term structural drivers including aging populations, advances in precision medicine, and ongoing innovation in biotechnology and genomics. Regulatory developments around drug pricing and approval pathways, along with macroeconomic factors such as interest rate expectations, influence capital allocation between established pharmaceutical firms and higher-risk innovative companies. Genomics-focused themes face elevated volatility tied to clinical trial outcomes and technological breakthroughs, while broader health care exposure provides stability through diversified revenue streams. Capital flows into the sector remain supported by demographic trends and research and development pipelines, though policy uncertainty and valuation compression in growth segments present ongoing considerations for investors.
Performance and Positioning Comparison
In recent market cycles, ARK Genomic Revolution ETF (ARKG) has exhibited greater sensitivity to shifts in investor sentiment toward high-growth biotechnology and genomics names, resulting in more pronounced movements during periods of sector rotation or interest rate changes. Its concentrated positioning amplifies the impact of individual company developments. Vanguard Health Care ETF (VHT), by contrast, has delivered more stable returns driven by the performance of large-cap pharmaceutical and managed care companies, with lower volatility attributable to its broad diversification across market capitalizations and subsectors. Relative positioning favors VHT for investors prioritizing cost efficiency and reduced drawdown risk, while ARKG suits those seeking differentiated exposure to emerging genomics technologies amid evolving innovation cycles.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Visit the AI Screener to explore current opportunities across sectors including health care.
Tickeron AI Verdict
Based on structural characteristics, Tickeron’s AI would currently favor Vanguard Health Care ETF (VHT) due to its significantly lower expense ratio, broader diversification across approximately 410 holdings, and established liquidity profile. These factors support more consistent risk-adjusted exposure within the health care sector compared to the higher-cost, concentrated thematic approach of ARK Genomic Revolution ETF (ARKG). Investors seeking thematic upside may still consider ARKG for its specialized genomics focus, though the probabilistic assessment prioritizes VHT for most allocation objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARKG is a Hold and VHT is a StrongBuy.
ARKG's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ARKG turned positive on October 28, 2026. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in 47 of 51 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ARKG as a result. In 72 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
ARKG moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARKG crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 22 of 23 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 248 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 202 of 220 cases where ARKG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for ARKG moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 28 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
VHT in upward trend: 10-day moving average crossed above 50-day moving average on October 16, 2026
The 10-day moving average for VHT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on VHT as a result. In 74 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for VHT just turned positive on October 12, 2026. Looking at past instances where VHT's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
VHT moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where VHT advanced for three days, in 252 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VHT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
VHT broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VHT entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
| ARKG | VHT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| Advances ODDS (%) | 3 days ago 90% | 2 days ago 81% |
| Declines ODDS (%) | 18 days ago 90% | 13 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 85% |
Advertisement
ARKG and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARKG has been loosely correlated with DNA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if ARKG jumps, then DNA could also see price increases.
| Ticker / NAME | Correlation To ARKG | 1D Price Change % | ||
|---|---|---|---|---|
| ARKG | 100% | -6.73% | ||
| DNA - ARKG | 62% Loosely correlated | -12.01% | ||
| FATE - ARKG | 60% Loosely correlated | -4.15% | ||
| PHR - ARKG | 59% Loosely correlated | -0.72% | ||
| EDIT - ARKG | 59% Loosely correlated | -8.87% | ||
| BFLY - ARKG | 57% Loosely correlated | -14.91% | ||
More | ||||
VHT and
Correlation & Price change
A.I.dvisor indicates that over the last year, VHT has been closely correlated with LLY. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if VHT jumps, then LLY could also see price increases.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SIO | 24.96 | 0.06 | +0.24% |
| Touchstone Strategic Income ETF (SIO) | |||
| PTNT | 24.66 | N/A | N/A |
| Corgi IP Licensing & Royalties ETF (PTNT) | |||
| WBIF | 36.54 | -0.19 | -0.53% |
| WBI BullBear Value 3000 ETF (WBIF) | |||
| IWMI | 48.89 | -0.65 | -1.31% |
| NEOS Russell 2000 High Income ETF (IWMI) | |||
| HIBL | 79.56 | -13.85 | -14.83% |
| Direxion Daily S&P 500 High Beta Bull 3X ETF (HIBL) | |||